WO2002002508A1 - Process for the preparation of substituted octanoyl amides - Google Patents
Process for the preparation of substituted octanoyl amides Download PDFInfo
- Publication number
- WO2002002508A1 WO2002002508A1 PCT/CH2001/000399 CH0100399W WO0202508A1 WO 2002002508 A1 WO2002002508 A1 WO 2002002508A1 CH 0100399 W CH0100399 W CH 0100399W WO 0202508 A1 WO0202508 A1 WO 0202508A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- formula
- alkoxy
- compound
- compounds
- Prior art date
Links
- 0 *C(C[C@@]([C@](C[C@@](*)C(N*)=O)O)N)Cc1cc(*)c(*)cc1 Chemical compound *C(C[C@@]([C@](C[C@@](*)C(N*)=O)O)N)Cc1cc(*)c(*)cc1 0.000 description 3
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/02—Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C247/00—Compounds containing azido groups
- C07C247/02—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton
- C07C247/12—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
- C07C57/42—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings having unsaturation outside the rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
- C07C69/734—Ethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/38—Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/32—Oxygen atoms
- C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
Definitions
- the invention relates to a process for the preparation of 2 (S) ,4 (S) , 5(S) , 1 (S)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl- octanoyl amides and their physiologically acceptable salts; and the new compounds used as intermediates in the multistage process.
- EP-A-0 678 503 ⁇ -amino- ⁇ -hydroxy- ⁇ -aryl-alkanecarbox- amides are described, which exhibit renin-inhibiting properties and could be used as antihypertensive agents in pharmaceutical preparations.
- the manufacturing procedures described are unsatisfactory in terms of the number of process steps and yields and are not suitable for an industrial process.
- a disadvantage of these processes is also that the total yields of pure diastereomers that are obtainable are too small.
- alkane- carboxamides can be prepared both in high total yields and in a high degree of purity, and that selectively pure diastereomers are obtainable, if the double bond of 2,7- dialkyl-8-aryl-4-octenic acid or 2, 7-dialkyl-8-aryl-4- octenic acid ester is simultaneously halogenated in the 5 position and hydroxylated in the 4 position under lactonization, the halolactone is converted to a hydroxylactone and then the hydroxy group is converted to a leaving group, the leaving group substituted with azide, the lactone amidated and then the azide converted to the amine group.
- the high yields and stereoselectivities in the individual process steps particular attention is drawn to the fact that substantially fewer by-products are formed in the azidation step.
- a primary object of the invention is a process for the preparation of compounds of formula I,
- Ri and R 2 are, independently of one another, H, C ⁇ -C 6 alkyl, C ⁇ -C 6 halogenalkyl, C ⁇ -C ⁇ alkoxy, C ⁇ -C 6 alkoxy-C ⁇ -C 6 alkyl, or C ⁇ -C 6 alkoxy-C ⁇ -C 6 alkyloxy,
- R 3 is C ⁇ -C 6 alkyl
- R 4 is C ⁇ -C 6 alkyl
- R 5 is C ⁇ -C 6 alkyl, C ⁇ -C 6 hydroxyalkyl, C ⁇ -C 6 alkoxy-C ⁇ -C 6 - alkyl, C ⁇ -C 6 alkanoyloxy-C ⁇ -C 6 alkyl, C ⁇ -C 6 aminoalkyl, C ⁇
- C 6 alkylamino-C ⁇ -C 6 -alkyl C ⁇ -C 6 -dialkylamino-C ⁇ -C 6 -alkyl, C ⁇ -C 3 - alkanoylamido-Ci-Cg-alkyl, HO (0) C-C ⁇ -C 6 -alkyl, Ci-C 6 alkyl-0- (0)C-C ⁇ -C 6 alkyl, H 2 N-C (0) -C ⁇ -C 6 alkyl, C ⁇ -C 6 alkyl-HN-C (0) -C ⁇ - C 6 alkyl or (d-C 6 alkyl) 2 N-C (0) -C ⁇ -C 6 -alkyl, comprising a) the reaction of a compound of formula II,
- R 6 is C ⁇ -C 20 alkyl , C 3 -C ⁇ 2 cycloalkyl , C 3 -C ⁇ 2 cycloalkyl- Ci-C ⁇ alkyl , C 6 -C ⁇ 0 aryl or C 6 -C ⁇ 0 -aryl-C ⁇ -C 6 alkyl, with a halogenation agent to form a compound of formula VI , or c2 ) a carboxylic acid of formula V, or a salt of this carboxylic acid,
- M is an alkali metal, an equivalent alkaline earth metal or the residue of an alcohol minus a hydroxyl group, e) hydrolysis of the compound of formula VII in the presence of an acid to form a compound of formula VIII,
- R ⁇ and R 2 may be linear or branched and preferably comprise 1 to 4 C atoms. Examples are methyl, ethyl, n- and i-propyl, n-, i- and t-butyl, pentyl and hexyl .
- Ri and R 2 may be linear or branched and preferably comprise 1 to 4 C atoms, especially 1 or 2 C atoms. Examples are fluoromethyl, difluoromethyl, trifluoro- methyl, chloromethyl, dichloromethyl, trichloromethyl, 2-chloroethyl and 2, 2, 2-trifluoroethyl .
- Ri and R 2 may be linear or branched and preferably comprise 1 to 4 C atoms. Examples are methoxy, ethoxy, n- and i-propyloxy, n-, i- and t-butyloxy, pentyloxy and hexyloxy.
- Ri and R 2 may be linear or branched.
- the alkoxy group preferably comprises 1 to 4 and especially 1 or 2 C atoms, and the alkyl group preferably comprises 1 to 4 C atoms.
- Examples are methoxymethyl, l-methoxyeth-2-yl, l-methoxyprop-3-yl, l-methoxybut-4-yl, methoxypentyl, methoxyhexyl, ethoxymethyl, l-ethoxyeth-2-yl, 1-ethoxyprop- 3-yl, l-ethoxybut-4-yl, ethoxypentyl, ethoxyhexyl, propyloxymethyl, butyloxy ethyl, l-propyloxyeth-2-yl and l-butyloxyeth-2-yl .
- Ri and R 2 may be linear or branched.
- the alkoxy group preferably comprises 1 to 4 and especially 1 or 2 C atoms, and the alkyoxy group preferably comprises 1 to 4 C atoms.
- Examples are methoxy ethyloxy, 1- methoxyeth-2-yloxy, l-methoxyprop-3-yloxy, l-methoxybut-4- yloxy, methoxypentyloxy, methoxyhexyloxy, ethoxyr ⁇ ethyloxy, l-ethoxyeth-2-yloxy, l-ethoxyprop-3-yloxy, l-ethoxybut-4- yloxy, ethoxypentyloxy, ethoxyhexyloxy, propyloxymethyloxy, butyloxymethyloxy, l-propyloxyeth-2-yloxy and 1-butyloxyeth- 2-yloxy.
- Ri is methoxy- or ethoxy-Ci- C 4 alkyloxy
- R 2 is preferably methoxy or ethoxy.
- Particularly preferred are compounds of formula I, wherein Ri is l-methoxyprop-3-yloxy and R 2 is methoxy.
- R 3 and R 4 may be linear or branched and preferably comprise 1 to 4 C atoms. Examples are methyl, ethyl, n- and i-propyl, n-, i- and t-butyl, pentyl and hexyl. In a preferred embodiment, R 3 and R 4 in compounds of formula I are in each case isopropyl.
- R 5 may be linear or branched in the form of alkyl and preferably comprise 1 to 4 C atoms. Examples of alkyl are listed hereinabove. Methyl, ethyl, n- and i- propyl, n-, i- and t-butyl are preferred.
- R 5 may be linear or branched and preferably comprise 2 to 6 C atoms. Some examples are 2-hydroxyethy-l-yl, 2-hydroxyprop-l-yl, 3-hydroxyprop-l-yl, 2-, 3- or 4-hydroxybut-l-yl, hydroxypentyl and hydroxyhexyl .
- R 5 may be linear or branched.
- the alkoxy group preferably comprises 1 to 4 C atoms and the alkyl group preferably 2 to 4 C atoms.
- Some examples are 2-methoxyethy-l-yl, 2-methoxyprop-l-yl, 3-methoxyprop-l-yl,
- R 5 may be linear or branched.
- the alkanoyloxy group preferably comprises 1 to 4 C atoms and the alkyl group preferably 2 to 4 C atoms. Some examples are formyloxymethyl, formyloxyethyl, acetyloxy- ethyl, propionyloxyethyl and butyroyloxyethyl .
- R 5 may be linear or branched and preferably comprise 2 to 4 C atoms. Some examples are 2- aminoethyl, 2- or 3-aminoprop-l-yl and 2-, 3- or 4-aminobut- 1-yl.
- R 5 may be linear or branched.
- the alkylamino group preferably comprises C ⁇ -C 4 alkyl groups and the alkyl group preferably 2 to 4 C atoms.
- Some examples are 2- methy1aminoeth-l-yl, 2-dimethylaminoeth-l-yl, 2-ethylamino- eth-l-yl, 2-ethylaminoeth-l-yl, 3-methylaminoprop-l-yl, 3- dir ⁇ ethylaminoprop-1-yl, 4-methylaminobut-l-yl and 4-dimethylaminobut-l-yl .
- R 5 may be linear or branched.
- the alkanoyl group preferably comprises 1 to 4 C atoms and the alkyl group preferably 1 to 4 C atoms.
- Some examples are 2-formamidoeth-l-yl, 2-acetar ⁇ idoeth-l-yl, 3- propionylamidoeth-1-yl and 4-butyroylamidoeth-l-yl .
- R 5 may be linear or branched and the alkyl group preferably comprises 2 to 4 C atoms. Some examples are carboxymethyl, carboxyet yl, carboxypropyl and carboxybutyl .
- R 5 may be linear or branched, and the alkyl groups preferably comprise independently of one another 1 to 4 C atoms.
- Some examples are methoxycarbonylmethyl, 2-methoxycarbonyleth-l-yl, 3- methoxycarbonylprop-1-yl, 4-methoxycarbonylbut-l-yl, ethoxy- carbonylmethyl, 2-ethoxycarbonyleth-l-yl, 3-ethoxycarbonyl- prop-1-yl, and 4-ethoxycarbonylbut-l-yl.
- R 5 may be linear or branched, and the alkyl group preferably comprises 2 to 6 C atoms.
- Some examples are carbamidomethyl, 2-carbamidoeth-l-yl, 2-carbamido-2 , 2-dimethyleth-l-yl, 2- or 3-carbamidoprop-l- yl , 2- , 3- or 4-carbamidobut-l-yl , 3-carbamido-2-methylprop- 1-yl, 3-carbamido-l , 2-dimethylprop-l-yl , 3-carbamido-3- methylprop-1-yl , 3-carbamido-2 , 2-dimethylprop-l-yl , 2- , 3- , 4- or 5-carbamidopent-l-yl, 4-carbamido-3 , 3- or -2 , 2- dimethylbut-1-yl .
- R 5 may be linear or branched, and the NH-alkyl group preferably comprises 1 to 4 C atoms and the alkyl group preferably 2 to 6 C atoms .
- Examples are the carbamidoalkyl groups defined hereinabove, whose N atom is substituted with one or two methyl, ethyl, propyl or butyl .
- a preferred subgroup of compounds of formula I is that in which Ri is C ⁇ C alkoxy or C ⁇ -C 4 alkoxy-C ⁇ -C alkyloxy, R 2 is Ci- C alkoxy, R 3 is C ⁇ -C alkyl , R 4 is C ⁇ -C 4 alkyl and R 5 is H 2 NC (0) - C ⁇ -C 6 alkyl which if necessary is N-monosubstituted or N-di-Ci- C 4 alkyl substituted .
- a more preferred subgroup of compounds of formula I is that in which R ⁇ is methoxy-C 2 -C -alkyloxy, R 2 is methoxy or ethoxy, R 3 is C 2 -C alkyl , R 4 is C 2 -C alkyl and R 5 is H 2 NC ( 0) -C ! - C 6 alkyl .
- An especially preferred compound of formula I is that in which R ⁇ is 3-methoxy-prop-3-yloxy, R 2 is methoxy, R 3 and R are 1-methyleth-l-yl, and R 5 is H 2 NC (0) - [C (CH 3 ) 2 ] -CH 2 - .
- R 6 may be linear or branched and comprise preferably 1 to 12 C atoms, 1 to 8 C atoms being especially preferred.
- R s is particularly preferred as a linear C ⁇ ⁇ C 4 alkyl.
- Some examples are methyl, ethyl and the isomers of propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tetradecyl, hexadecyl, octacyl and eicosyl.
- methyl and ethyl are especially preferred.
- R 6 may preferably comprise 4 to 8 ring- carbon atoms, 5 or 6 being especially preferred. Some examples are cyclopropyl, cyclobutyl, cyclopentyl, cyclohe- xyl, cyclooctyl and cyclododecyl .
- R 6 may comprise preferably 4 to 8 ring-carbon atoms, 5 or 6 being especially preferred, and preferably 1 to 4 C atoms in the alkyl group, 1 or 2 C atoms being especially preferred.
- Some examples are cyclopropyl methyl, cyclobutyl methyl, cyclopentyl methyl or cyclopentyl ethyl, and cyclohexyl methyl or cyclohexyl ethyl.
- R 6 is preferably phenyl or naphthyl.
- R 6 is preferably benzyl or phenyl ethyl.
- M may be an alkaline earth metal, for example Mg, Ca or Sr. Equivalent in the context of the invention means the charge equalization of cation and anion. M is preferably an alkali metal, for example Li, Na or K. Particular preference is for M as Li . If M is the residue of an alcohol minus a hydroxyl group, it may be the R 6 group, including the embodiments and preferences described hereinbefore, in particular alkyl and cycloalkyl.
- Residue A in the leaving group AO is preferably the residue of an organic acid, for example C ⁇ -C 8 acyl, particular preference being for C ⁇ -C 8 sulfonyl .
- the acyl residue may be a carboxylic acid, such as formic acid, acetic acid, propionic acid, butyric acid and benzoic acid substituted if necessary with C ⁇ -C 4 alkyl, C ⁇ -Calkoxy or halogen.
- the sulfonyl residue A may correspond for example to formula R 7 -S0 2 -, wherein R 7 is Ci-C 8 alkyl, C ⁇ -C 8 halogenalkyl, C 3 -C 8 cycloalkyl, or phenyl or benzyl either unsubstituted or substituted with C ⁇ -Calkyl, C ⁇ -C 4 alkoxy, C ⁇ -C 4 hakogenalkyl or halogen.
- sulfonyl residues are methyl, ethyl, phenyl, methylphenyl, dimethyl phenyl, trimethyl phenyl, trifluoromethyl phenyl, chlorophenyl, dichlorophenyl, bromophenyl, dibromophenyl and trifluoromethyl sulfonyl.
- solvents are water and organic solvents, especially polar organic solvents, which can also be used as mixtures of at least two solvents.
- solvents are hydrocarbons (petroleum ether, pentane, hexane, cyclohexane, methylcyclohexane, benzene, toluene, xylene) , halogenated hydrocarbon (dichloromethane, chloroform, tetrachloroethane, chlorobenzene) ; ether (diethyl ether, dibutyl ether, tetrahydrofuran, dioxane, ethylene glycol dimethyl or diethyl ether) ; carbonic esters and lactones
- Reduction of the azide group to the amine group in the compounds of formula III takes place in a manner known per se (see Chemical Reviews, Vol. 88 (1988), pages 298 to 317), for example using metal hydrides or more expediently using a catalytic method with hydrogen in the presence of homogeneous (Wilkinson catalyst) or heterogeneous catalysts, for example Raney nickel or precious metal catalysts such as platinum or palladium, if necessary on substrates such as carbon.
- the hydrogenation can also be carried out if necessary catalytically under phase transfer conditions, for example with ammonium formate as hydrogen donor. It is of advantage to use organic solvents.
- the reaction temperature may range for example from approximately 0°C to 200°C and preferably from 10°C to 100°C. Hydrogenation may be carried out at normal pressure or increased pressure up to 100 bar, for example, and preferably up to 50 bar.
- the compounds of formula I may be converted to addition salts in a manner known per se by treatment with monobasic or polybasic, inorganic or organic acids. Hemifumarates are preferred.
- Suitable chlorination, bromination and iodination agents are elemental bromine and iodine, in particular N-chlorine, N-bromine and N-iodocarboxamides and dicarboximides .
- Preferred are N-chloro, N-bromo and N-iodophthalimide and especially chloro, N-bromo and N-iodosuccinimide, as well as tertiary butyl hypochlorite and N-halogenated sulfonamides and sulfoni ides, for example chloramine T.
- the reaction is advantageously carried out in organic solvents miscible with water, such as tetrahydrofuran or dioxane in the presence of at least an equivalent volume of water.
- the reaction takes place first at low temperatures, for example -20 to 10°C, and then at elevated temperatures, for example 30 to 100°C.
- inorganic or organic acids may be advantageous. Suitable acids are for example formic acid, acetic acid, methanesulfonic acid, trifluoroacetic acid, trifluoromethanesulfonic acid, toluenesulfonic acid, H 2 S0 4 , H 3 P0, hydrogen halides, acid ion exchange resins, and acids immobilized on solid carriers.
- the halolactone may be isolated for example by extraction with organic solvents.
- Suitable salts of carboxylic acids of formula V are for example alkali metal or alkaline earth metal salts, for example sodium, potassium, magnesium or calcium salts, as well as ammonium salts.
- the ammonium salts may derive from ammonia, primary, secondary or tertiary amines, or they may be quaternary ammonium salts.
- the amines may be acyclic or cyclic and comprise heteroatoms from the 0 and S group.
- the amines may comprise 1 to 18 C atoms, 1 to 12 being preferred and 1 to 8 especially preferred.
- Quaternary ammonium salts may comprise 4 to 18 C atoms, 4 to 12 being preferred and 4 to 8 especially preferred.
- amines are ethylamine, dimethylamine, triethylamine, ethylamine, diethylamine, triethylamine, propylamine, dipropylamine, Tripropylamine, isopropylamine, butylamine, dibutylamine, tributylamine, phenylamine, methylethylamine, methyldiethylamine, phenylmethy1amine, benzyla ine, cyclo- pentylamine, cyclohexylamine, piperidine, N-methyl- piperidine, morpholine, pyrrolidine, and 2-phenylethylamine.
- Salt formation allows a more efficient purification of the carboxylic acids of formula V with regard to their optical and chemical purity, especially when crystalline salts are formed with the selection of amines.
- the salts may be converted before the reaction to the carboxylic acids of formula V.
- the salts may also be used directly for halolactonization. In this case, the addition of acids, for example trifluoroacetic acid or other strong acids, is recommended, as described under process step cl) .
- reaction of a compound of formula VI with at least equir ⁇ olar quantities of alkali or alkaline earth metal hydroxides is expediently carried out in a polar organic solvent, for example alcohols such as isopropanol, and at low temperatures of, for example, -20 to 30°C.
- a polar organic solvent for example alcohols such as isopropanol
- Aqueous solutions of hydroxides are preferably used, lithium hydroxide being especially preferred.
- the compound of formula VII does not need to be isolated, but the reaction mixture can be used directly in process step e) .
- the desired stereoisomer is also formed in this step at high yields of up to 90% or more.
- Conversion of the hydroxy group to a leaving group may be carried out in organic solvents, preferably polar organic solvents, and at temperatures of -20 to 50°C.
- Acid halogenides such as acid chlorides and acid bromides, are preferably used as reagents. Sulfonyl chlorides or bromides are especially preferred.
- the reaction is advantageously carried out in the presence of equivalent quantities of a base for bonding of the acid. Suitable bases are in particular tertiary amines, such as trimethylamine or triethylamine and dimethylaminopyridine.
- the hydroxylactone of a compound of formula VII may be isolated for example by extraction with organic solvents. The yields are up to 90% or more.
- Suitable azidation agents are for example metal azides, especially alkaline earth metal azides and alkali metal azides, as well as silyl azides. Especially preferred azidation agents are lithium azide, sodium azide and potassium azide.
- the reaction may be carried out in organic solvents, such as 1, 3-dimethyl-3, 4, 5, 6-tetrahydro-2 (1H) - pyrimidinone (DMPU) , di ethylacetamide (DMA) , N- methylpyrrolidone (NMP) , dimethylformamide (DMF), 1,3- dimethylimidazolidinone (DMI), toluene or methylcyclohexane.
- organic solvents such as 1, 3-dimethyl-3, 4, 5, 6-tetrahydro-2 (1H) - pyrimidinone (DMPU) , di ethylacetamide (DMA) , N- methylpyrrolidone (NMP) , dimethylformamide (DMF), 1,3- dimethylimi
- the introduction of the leaving group in process step f) and the azidation in process step g) may be carried out simultaneously in one reaction vessel.
- the azidation may also be carried out directly with the hydroxyl compound of formula VIII.
- This reaction has been described by David. L. Hughes in Organic Preparations and Procedures Int. (1996), 28 (2), pp. 127-164 and by M. C. Viaud et al. in Synthesis (1990), pp. 130 to 131.
- the azidation is carried out with at least equimolar quantities of zinc azide/bis-pyridine in the presence of, for example, triphenylphosphine in quantities of 2 equivalents or more, and approximately equal quantities of an azodicarboxylate such as azodiisopropylcarboxylate .
- the reaction is carried out in an organic solvent, especially an aromatic hydrocarbon, such as benzene, toluene or xylene.
- the reaction temperature may be -20 to 80°C.
- a further object of the invention is thus a compound of formula X,
- Ri and R 2 are, independently of one another, H, C ⁇ -C 6 alkyl , Ci-C ⁇ halogenalkyl, C ⁇ -C 6 alkoxy, C ⁇ -C 6 alkoxy-C ⁇ -C 6 alkyl , or Ci- C 6 alkoxy-C ⁇ -C 6 alkyloxy, R 3 is C ⁇ -C 6 alkyl , R 4 is C ⁇ -C 6 alkyl , and R 5 is Ci-C 6 alkyl, C ⁇ -C 6 hydroxyalkyl, C ⁇ -C 6 alkoxy-C ⁇ -C 6 -alkyl, Ci-Cgalkanoyloxy-Ci-Csalk l , C ⁇ -C 6 aminoalkyl , C ⁇ -C 6 alkylamino- Ci-C ⁇ -alkyl , Cx-C ⁇ -dialkylamino-Ci-C ⁇ -alkyl , C !
- a further object of the invention is a compound of formula XI,
- Ri and R 2 are, independently of one another, H, C ⁇ -C 6 alkyl, Ci-C ⁇ halogenalkyl, C ⁇ -C 6 alkoxy, d-C 6 alkoxy-d-C 6 alkyl, or Ci- C 6 alkoxy-C ⁇ -C 6 alkyloxy, R 3 is C ⁇ -C 6 alkyl, R is C ⁇ -C 6 alkyl, and R 5 is C ⁇ -C 6 alkyl, d-C 6 hydroxyalkyl, C ⁇ -C 6 alkoxy-C ⁇ -C 6 -alkyl, C ⁇ -C 6 alkanoyloxy-C ⁇ -C 6 alkyl, C ⁇ -C 6 aminoalkyl, C ⁇ -C 3 alkylamino- C ⁇ -C 6 -alkyl, C ⁇ -C 6 -dialkylamino-C ⁇ -C 6 -alkyl, C ⁇ -C 6 -alkanoyl- amido-C ⁇ -C 6 -alkyl, HO (0) C-
- Ri and R 2 are, independently of one another, H, d-C 6 alkyl , d-C 6 halogenalkyl, C ⁇ -C 6 alkoxy, d-C 6 alkoxy-C ⁇ -C 6 alkyl, or d- C s alkoxy-C -C 3 alkyloxy, R 3 is C ⁇ -C 6 alkyl , R 4 is C ⁇ -C 6 alkyl , and R 5 is C ⁇ -C 6 alkyl, C ⁇ -C 6 hydroxyalkyl, C ⁇ -C 6 alkoxy-C ⁇ -C 6 -alkyl , C ⁇ -C 6 alkanoyloxy-C ⁇ -C 6 alkyl, C ⁇ -C 6 aminoalkyl , C ⁇ -C 6 alkylamino- C ⁇ -C 6 -alkyl , d-C 6 -dialkylamino-C ⁇ -C 6 -alkyl , C ⁇ -C 3 -alkanoyl- amido-Ci-C
- M is an alkali metal, an equivalent alkaline earth metal or the residue of an alcohol minus a hydroxyl group
- R ⁇ is an alkali metal, an equivalent alkaline earth metal, hydrogen or the residue of an alcohol minus a hydroxyl group
- the residue of the reaction is expediently taken up with an aqueous acid, such as hydrochloric acid, and the compound of formula V is extracted (for example with ethers) and purified.
- the hydrolysis is quantitative, and the pure compound of formula V is obtained in yields of more than 90%. It is possible to carry out the hydrolysis at the same time as the halolactonization in one reaction vessel. The hydrolysis may also be carried out enzymatically.
- Ri to R 4 , and Rn are as defined hereinbefore, including the preferences, Y is Cl, Br or I, and Z is Cl, Br or I, in the presence of an alkali metal or alkaline earth metal. Y and Z are preferably Br and especially Cl .
- Grignard reagents with alkenyl halogenides in an ether such as tetrahydrofuran or dioxane as solvents in the presence of catalytic quantities of a soluble metal salt or metal complex for example an iron, nickel or palladium salt or an iron, nickel or palladium complex (such as iron trichloride, iron acetonyl acetate iron benzoyl acetonate, nickel acetonyl acetate, and iron, nickel or palladium complexes with tertiary phosphines or ditertiary diphosphines such as triphenylphosphine, tricyclohexyl- phosphine, 1, 2-diphenylphosphinoethane, 1, 2-diphenyl- phosphinopropane, 1, 2-diphenylphosphinofuran, and 1,2-di- p enylphosphinobutane is known.
- metal complexes and metal complex salts are dichloronickel (1, 2-diphenyl- phosphinoethane) and dichloropalladium(l, 2-diphenylphosphinoethane) .
- the presence of an additive stabilizing the metal salts or metal complexes and metal complex salts can be of advantage.
- Examples are DMPU, N-methylpyrrolidone, N,N-dimethylformamide, N,N-dimethylacetamide, N-methyl- morpholine, amines such as triethylamine and tetrar ⁇ ethylethylenediar ⁇ ine, as well as mixtures of at least two of these additives.
- the reaction is described by G. Cahiez et al . in Synthesis (1998), pp. 1199-1200.
- the reaction temperature may for example be -50 to 80°C, preferably -20 to 50°C.
- Catalytic quantities may for example be 0.1 to 20% by weight in relation to a compound of formula XIV. It is expedient to carry out the reaction so that initially a compound of formula XIV is converted to a Grignard compound (for example with magnesium) and then adding a solution of a compound of formula XV, metal salt, metal complex, or metal complex salt and the stabilizing additive, or vice versa.
- Catalytic quantities may for example be 0.1 to 10 mol per cent, preferably 1 to 5 mol per cent, in relation to compounds of formula XIV or XV.
- the compounds of formula XV are obtainable by reacting for example carbonic esters or derivatives of formula R 4 CH 2 COORu with 1, 3-dihalogenpropene in the presence of strong amine bases such as alkali metal amides (Li-N (i-propyl) 2 or lithium hexamethyldisilazane) to form compounds of formula XV, or by preparing through derivatization in a manner known per se carboxylic acids, carboxylic acid halogenides, carboxamides and carboxylic acid salts from e.g. the carbonic esters of formula XV.
- strong amine bases such as alkali metal amides (Li-N (i-propyl) 2 or lithium hexamethyldisilazane)
- the desired enantiomers can be obtained from the racemates in a manner known per se by separating the racemates, for example by crystallization from addition salts of carboxylic acids using optically active bases. It is more advantageous to separate the racemates by treating esters of formula XV with esterases.
- the compounds of formula I which per se are complex compounds, can be prepared in a convergent and simple manner, which is especially true for this enantioselective or diastereoselective synthesis.
- the total yield from all process steps a) to h) may amount to 40% or more, which makes industrial application feasible.
- a mixture of 9.75 g magnesium powder and 100 ml tetrahydrofuran is heated to reflux, and 0.50 ml 1,2- dibromoethane then added over a period of 1 minute (visible exothermic reaction).
- a solution of 34.63 g A' , 3.80 ml 1,2- dibromoethane and 300 ml tetrahydrofuran is added dropwise over a period of 30 minutes at 62 - 64 °C. The mixture is agitated for another 30 minutes under reflux and then cooled down to ambient temperature.
- the reaction mixture is filtered under argon until clear and the resulting Grignard solution added dropwise over a period of 10 minutes to a solution of 20.47 g Al, 0.24 ml N-methylpyrrolidone, 0.88 g iron (III) acetylacetonate in 230 ml tetrahydrofuran at -5 to 0°C.
- the reaction mixture is stirred for a further 1 minute at 0°C, and 400 ml 2N hydrochloric acid is then added.
- the mixture is now extracted with diethyl ether (3x 300 ml) and the organic phases washed consecutively with water (lx 300 ml) and saturated aqueous sodium chloride solution (lx 200 ml) .
- Example A2 By analogy with example Al, the derivative is prepared by reacting A' with A2 :
- a solution of 0.449 g B 1, 3.3 ml tetrahydrofuran and 1.7 ml water is cooled to 0°C.
- 0.205 g N-bromosuccinimide is added to the solution and the mixture stirred for 30 minutes at 0°C and for 15 hours at 70°C.
- the reaction mixture is cooled to 0°C and added to 30 ml of 40% aqueous sodium hydrogen sulfite solution that has been cooled to 0°C.
- the mixture is extracted with ethyl acetate (3x 50 ml) .
- R i2 is 4-BrC 6 H 5 -S0 2 - (G2) .
- F 1 and 5 ml dichloromethane 0.307 g 4-bromobenzenesulfochloride and 0.147 g 4- dimethylaminopyridine are consecutively added and the mixture then stirred for 24 hours at room temperature.
- the reaction mixture is poured onto iced water (30 ml) and extracted with diethyl ether (3x 30 ml) .
- the organic phases are washed consecutively with 5% aqueous sodium hydrogencarbonate solution (30 ml) and concentrated aqueous NaCl solution (30 ml) .
- R 12 is 4-CH 3 C 6 H 5 -S0 2 - ( G3 ]
- 0.229 g 4-methylbenzenesulfochloride and 0.147 g 4- dimethylaminopyridine are added and the mixture then stirred for 24 hours at room temperature.
- the reaction mixture is poured onto iced water (30 ml) and extracted with diethyl ether (3x 30 ml) .
- the organic phases are washed consecutively with 5% aqueous sodium hydrogencarbonate solution (30 ml) and concentrated, aqueous NaCl solution (30 ml) .
- a mixture of 9.5 g Gl, 2.35 g sodium azide and 100 ml 1.3- dimethyl-3, 4, 5, 6-tetrahydro-2 (1H) -pyrimidone is stirred for 20 hours at 60°C.
- the reaction mixture is poured onto 500 ml water and extracted with tert-butyl methyl ether (3x 200 ml) .
- the organic phases are washed consecutively with water (3 x 500 ml) , 5% aqueous sodium hydrogencarbonate solution (200 ml) and concentrated aqueous NaCl solution (200 ml) .
- the combined organic phases are dried over sodium sulfate and concentrated on a rotary evaporator.
- Example H3 Preparation of Jl A mixture of 4.62 g Hi, ' 3.48 g 3-amino-2,2- di ethylpropionamide and 0.95 g 2-hydroxypyridine is stirred over a period of 24 hours at 65 C. The cooled reaction mixture is extracted between tert-butyl methyl ether (2x 100 ml) and water (2x 100 ml) . The combined organic phases are dried over sodium sulfate, filtered and concentrated on a rotary evaporator. The residue is dried and crude title compound Jl is obtained as an oil (5.75 g, quantitative) (HPLC assay: > 95%) .
- the residue is mixed with 7.31 g fumaric acid and dissolved in 200 ml ethanol and filtered until clear.
- the filtrate is concentrated by evaporation to a total weight of 104 g and dissolved in 1.7 1 acetonitrile at 35°C.
- the resulting solution is inoculated with 10 mg of title compound (hemifumarate) and stirred for 17 hours at ambient temperature.
- the suspension is cooled to 0°C and filtered off by suction after 2 hours.
- the residue is washed with acetonitrile (3 x 200 ml) and then dried in a vacuum at
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Furan Compounds (AREA)
- Epoxy Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
Description
Claims
Priority Applications (19)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU0301463A HU228526B1 (en) | 2000-07-05 | 2001-06-26 | Process for the preparation of substituted octanoyl amides and the intermediates |
IL15371701A IL153717A0 (en) | 2000-07-05 | 2001-06-26 | Process for teh preparation of substituted octanoyl amides |
AU2001273763A AU2001273763B2 (en) | 2000-07-05 | 2001-06-26 | Process for the preparation of substituted octanoyl amides |
CA002414847A CA2414847C (en) | 2000-07-05 | 2001-06-26 | Process for the preparation of substituted octanoyl amides |
EP01940047A EP1296935B1 (en) | 2000-07-05 | 2001-06-26 | Process for the preparation of substituted octanoyl amides |
AU7376301A AU7376301A (en) | 2000-07-05 | 2001-06-26 | Process for the preparation of substituted octanoyl amides |
PL358887A PL212898B1 (en) | 2000-07-05 | 2001-06-26 | Process for the preparation of substituted octanoyl amides |
JP2002507765A JP4900755B2 (en) | 2000-07-05 | 2001-06-26 | Process for the preparation of substituted octanoylamides |
KR1020027017207A KR100690471B1 (en) | 2000-07-05 | 2001-06-26 | Process for the preparation of substituted octanoyl amides |
DK01940047T DK1296935T3 (en) | 2000-07-05 | 2001-06-26 | Process for the preparation of substituted octanoylamides |
NZ523088A NZ523088A (en) | 2000-07-05 | 2001-06-26 | Process for the preparation of substituted octanoyl amides, the compounds and intermediates thereof |
DE60138099T DE60138099D1 (en) | 2000-07-05 | 2001-06-26 | METHOD FOR THE PRODUCTION OF SUBSTITUTED OCTANOYL AMIDES |
MXPA02012628A MXPA02012628A (en) | 2000-07-05 | 2001-06-26 | Process for the preparation of substituted octanoyl amides. |
US10/312,987 US6730798B2 (en) | 2000-07-05 | 2001-06-26 | Process for the preparation of substituted octanoyl amides |
BRPI0112362-9B1A BR0112362B1 (en) | 2000-07-05 | 2001-06-26 | Process for the preparation of substituted octanoyl amides and intermediate compounds |
IL153717A IL153717A (en) | 2000-07-05 | 2002-12-27 | Process for the preparation of 2, 7- dialkyl-4- hydroxy- 5-amino-8-aryl-octanoyl amides |
NO20030012A NO328105B1 (en) | 2000-07-05 | 2003-01-02 | Process for the preparation of substituted octanoylamides and their intermediates |
IL187796A IL187796A (en) | 2000-07-05 | 2007-11-29 | Intermediates of substituted octanoyl amides |
IL187795A IL187795A (en) | 2000-07-05 | 2007-11-29 | Intermediates of substituted octanoyl amides |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH1329/00 | 2000-07-05 | ||
CH13292000 | 2000-07-05 | ||
CH24502000 | 2000-12-15 | ||
CH2450/00 | 2000-12-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002002508A1 true WO2002002508A1 (en) | 2002-01-10 |
Family
ID=25738979
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CH2001/000399 WO2002002508A1 (en) | 2000-07-05 | 2001-06-26 | Process for the preparation of substituted octanoyl amides |
Country Status (24)
Country | Link |
---|---|
US (1) | US6730798B2 (en) |
EP (1) | EP1296935B1 (en) |
JP (1) | JP4900755B2 (en) |
KR (1) | KR100690471B1 (en) |
CN (1) | CN100482636C (en) |
AR (1) | AR029564A1 (en) |
AT (1) | ATE426592T1 (en) |
AU (2) | AU2001273763B2 (en) |
BR (1) | BR0112362B1 (en) |
CA (1) | CA2414847C (en) |
CY (1) | CY1109110T1 (en) |
DE (1) | DE60138099D1 (en) |
DK (1) | DK1296935T3 (en) |
ES (1) | ES2322547T3 (en) |
HK (1) | HK1093201A1 (en) |
HU (1) | HU228526B1 (en) |
IL (4) | IL153717A0 (en) |
MX (1) | MXPA02012628A (en) |
NO (1) | NO328105B1 (en) |
NZ (1) | NZ523088A (en) |
PL (1) | PL212898B1 (en) |
PT (1) | PT1296935E (en) |
TW (1) | TWI289551B (en) |
WO (1) | WO2002002508A1 (en) |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003103653A1 (en) * | 2002-06-11 | 2003-12-18 | Elan Pharmaceuticals, Inc. | Methods of treating alzheimer's disease using aryl alkanoic acid amides |
WO2007006532A1 (en) | 2005-07-11 | 2007-01-18 | Novartis Ag | New pyrocatechin derivatives |
GB2431649A (en) * | 2005-10-25 | 2007-05-02 | Novartis Ag | Alternative synthesis of aryl-octanoyl amide compounds |
GB2431645A (en) * | 2005-10-25 | 2007-05-02 | Novartis Ag | Alternative synthesis of aryl-octanoyl amide compounds |
WO2008061622A1 (en) * | 2006-11-07 | 2008-05-29 | Novartis Ag | Crystalline forms of aliskiren hemifumarate |
EP1958666A1 (en) | 2007-02-13 | 2008-08-20 | Speedel Experimenta AG | Heterocyclic-substituted alkanamides as therapeutic compounds |
DE102007049039A1 (en) | 2007-10-11 | 2009-04-16 | Reuter Chemischer Apparatebau Kg | Process for the preparation of 8-hydrazino-8-aryl-octanoyl derivatives and their use |
WO2009064479A1 (en) * | 2007-11-13 | 2009-05-22 | Teva Pharmaceutical Industries Ltd. | Polymorphic forms of aliskiren hemifumarate and process for preparation thereof |
EP2062874A1 (en) | 2007-11-20 | 2009-05-27 | KRKA, tovarna zdravil, d.d., Novo mesto | Process and intermediates for the preparation of aliskiren |
EP2189442A1 (en) | 2008-11-20 | 2010-05-26 | Krka Tovarna Zdravil, D.D., Novo Mesto | Process and intermediates for the preparation of aliskiren |
WO2010089105A2 (en) | 2009-02-05 | 2010-08-12 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Moisture-activated granulation process |
US7872153B2 (en) | 2006-03-21 | 2011-01-18 | Novartis Ag | Salt of aliskiren with sulfuric acid |
US8203005B2 (en) | 2009-10-29 | 2012-06-19 | Carbo Design Llc | Manufacturing process for enantiomerically pure 8-aryloctanoic acids as Aliskiren |
EP2551260A1 (en) | 2011-07-28 | 2013-01-30 | Chemo Ibérica, S.A. | Chemical process for opening ring compounds |
US8445708B2 (en) | 2005-10-28 | 2013-05-21 | Reuter Chemischer Apparatebau Kg | Process for preparing chiral octenoic acid derivatives |
US8703976B2 (en) | 2011-10-02 | 2014-04-22 | Milan Soukup | Manufacturing process for 8-aryloctanoic acids such as Aliskiren |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0419361D0 (en) | 2004-08-31 | 2004-10-06 | Novartis Ag | Organic compounds |
GB0511686D0 (en) | 2005-06-08 | 2005-07-13 | Novartis Ag | Organic compounds |
GB0519764D0 (en) | 2005-09-28 | 2005-11-09 | Novartis Ag | Organic compounds |
AR063597A1 (en) * | 2006-11-09 | 2009-02-04 | Novartis Ag | NEW SALT |
CN102036948A (en) * | 2008-05-23 | 2011-04-27 | 特瓦制药工业有限公司 | Aliskiren monofumarate and processes for preparation thereof |
US8148576B2 (en) * | 2009-02-05 | 2012-04-03 | Teva Pharmaceutical Industries Ltd. | Solid state forms of aliskiren compounds |
WO2011028919A2 (en) | 2009-09-03 | 2011-03-10 | Teva Pharmaceutical Industries Ltd. | Solid forms of aliskiren hemifumarate and processes for preparation thereof |
US20110113995A1 (en) * | 2009-11-13 | 2011-05-19 | Lindsay Corporation | Method and apparatus for planting and irrigation |
WO2011148392A1 (en) * | 2010-05-28 | 2011-12-01 | Msn Laboratories Limited | Process for the preparation of (2s,4s,5s,7s)-n-(2-carbamyl-2- methylpropyl)-5-amino-4-hydroxy-2,7-diisopropyl-8-[4-methoxy-3-(3- methoxypropoxy)phenyl]-octanamide hemifumarate and its intermediates thereof |
EP2630118B1 (en) | 2010-10-19 | 2014-11-05 | Mylan Laboratories Limited | Synthesis of aliskiren |
ITMI20110893A1 (en) * | 2011-05-19 | 2012-11-20 | Chemelectiva S R L | PROCESSES AND INTERMEDIATES FOR THE SYNTHESIS OF ALISKIREN |
WO2013118138A1 (en) | 2011-12-13 | 2013-08-15 | Laboratories Ltd Mylan | Novel process for the preparation of renin inhibitors |
US9090537B2 (en) | 2012-02-17 | 2015-07-28 | Mylan Laboratories Limited | Process for the preparation of aliskiren |
WO2013124868A2 (en) | 2012-02-21 | 2013-08-29 | Mylan Laboratories Limited | Solid form of aliskiren intermediate |
WO2013144979A1 (en) | 2012-03-28 | 2013-10-03 | Maylan Laboratories Ltd | Process for the preparation of aliskiren |
WO2013171767A1 (en) | 2012-05-18 | 2013-11-21 | Mylan Laboratories Limited | An improved process for the preparation of aliskiren |
CN106220528B (en) * | 2014-02-28 | 2018-05-08 | 华润双鹤药业股份有限公司 | 4- positions epimer, the preparation method and the usage of aliskiren |
CN106146339B (en) * | 2015-04-23 | 2018-02-23 | 华润双鹤药业股份有限公司 | 5 epimers, preparation method and the usages of aliskiren |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0678514A1 (en) * | 1994-04-18 | 1995-10-25 | Ciba-Geigy Ag | 3,5-Disubstituted tetrahydrofuran-2-ones |
EP0678500A1 (en) * | 1994-04-18 | 1995-10-25 | Ciba-Geigy Ag | Alpha-amino alkanoic acids and reduction products as intermediates in the preparation of renin inhibitors |
EP0678503A1 (en) * | 1994-04-18 | 1995-10-25 | Ciba-Geigy Ag | Delta-amino-gamma-hydroxy-omega-aryl alkanoic acid amides with enzyme especially renin inhibiting activities |
WO2001009083A1 (en) * | 1999-07-29 | 2001-02-08 | Speedel Pharma Ag | Production of n-substituted 2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylamides |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4492799A (en) * | 1979-07-02 | 1985-01-08 | Union Carbide Corporation | Halo-4-alkenoic acids and their use as pesticidal intermediates |
FR2666757B1 (en) * | 1990-09-14 | 1992-12-18 | Usinor Sacilor | SHEET FOR A CONTINUOUS CASTING CYLINDER OF METALS, ESPECIALLY STEEL, BETWEEN CYLINDERS OR ON A CYLINDER. |
DE59504502D1 (en) * | 1994-07-18 | 1999-01-21 | Siemens Ag | CASTING ROLLER WEAR PROTECTIVE LAYER |
AU7418198A (en) * | 1997-05-23 | 1998-12-11 | Voest-Alpine Industrieanlagenbau Gmbh | Casting cylinder for thin-band continuous casting installation |
-
2001
- 2001-06-26 WO PCT/CH2001/000399 patent/WO2002002508A1/en active Application Filing
- 2001-06-26 CA CA002414847A patent/CA2414847C/en not_active Expired - Fee Related
- 2001-06-26 PT PT01940047T patent/PT1296935E/en unknown
- 2001-06-26 IL IL15371701A patent/IL153717A0/en unknown
- 2001-06-26 JP JP2002507765A patent/JP4900755B2/en not_active Expired - Lifetime
- 2001-06-26 ES ES01940047T patent/ES2322547T3/en not_active Expired - Lifetime
- 2001-06-26 DE DE60138099T patent/DE60138099D1/en not_active Expired - Lifetime
- 2001-06-26 EP EP01940047A patent/EP1296935B1/en not_active Expired - Lifetime
- 2001-06-26 HU HU0301463A patent/HU228526B1/en not_active IP Right Cessation
- 2001-06-26 BR BRPI0112362-9B1A patent/BR0112362B1/en not_active IP Right Cessation
- 2001-06-26 AT AT01940047T patent/ATE426592T1/en active
- 2001-06-26 MX MXPA02012628A patent/MXPA02012628A/en active IP Right Grant
- 2001-06-26 CN CNB018122817A patent/CN100482636C/en not_active Expired - Lifetime
- 2001-06-26 KR KR1020027017207A patent/KR100690471B1/en active IP Right Grant
- 2001-06-26 NZ NZ523088A patent/NZ523088A/en not_active IP Right Cessation
- 2001-06-26 US US10/312,987 patent/US6730798B2/en not_active Expired - Lifetime
- 2001-06-26 AU AU2001273763A patent/AU2001273763B2/en not_active Ceased
- 2001-06-26 DK DK01940047T patent/DK1296935T3/en active
- 2001-06-26 AU AU7376301A patent/AU7376301A/en active Pending
- 2001-06-26 PL PL358887A patent/PL212898B1/en unknown
- 2001-06-29 TW TW090115929A patent/TWI289551B/en not_active IP Right Cessation
- 2001-07-04 AR ARP010103194A patent/AR029564A1/en active IP Right Grant
-
2002
- 2002-12-27 IL IL153717A patent/IL153717A/en not_active IP Right Cessation
-
2003
- 2003-01-02 NO NO20030012A patent/NO328105B1/en not_active IP Right Cessation
-
2006
- 2006-12-19 HK HK06113953.2A patent/HK1093201A1/en not_active IP Right Cessation
-
2007
- 2007-11-29 IL IL187796A patent/IL187796A/en not_active IP Right Cessation
- 2007-11-29 IL IL187795A patent/IL187795A/en not_active IP Right Cessation
-
2009
- 2009-05-28 CY CY20091100571T patent/CY1109110T1/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0678514A1 (en) * | 1994-04-18 | 1995-10-25 | Ciba-Geigy Ag | 3,5-Disubstituted tetrahydrofuran-2-ones |
EP0678500A1 (en) * | 1994-04-18 | 1995-10-25 | Ciba-Geigy Ag | Alpha-amino alkanoic acids and reduction products as intermediates in the preparation of renin inhibitors |
EP0678503A1 (en) * | 1994-04-18 | 1995-10-25 | Ciba-Geigy Ag | Delta-amino-gamma-hydroxy-omega-aryl alkanoic acid amides with enzyme especially renin inhibiting activities |
WO2001009083A1 (en) * | 1999-07-29 | 2001-02-08 | Speedel Pharma Ag | Production of n-substituted 2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylamides |
WO2001009079A1 (en) * | 1999-07-29 | 2001-02-08 | Speedel Pharma Ag | 2-alkyl-5-halogen-pent-4-ene carboxylic acids and their production |
Non-Patent Citations (4)
Title |
---|
GOSCHKE R ET AL: "Design and synthesis of novel 2,7-dialkyl substituted 5(S)-amino-4(S)-hydroxy-8-phenyl-octanecarboxamides as in vitro potent peptidomimetic inhibitors of human renin", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 7, no. 21, 4 November 1997 (1997-11-04), pages 2735 - 2740, XP004136522, ISSN: 0960-894X * |
PETER HEROLD ET AL: "A Versatile and Stereocontrolled Synthesis of Hydroxyethylene Dipeptide Isosters", JOURNAL OF ORGANIC CHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, US, vol. 54, no. 5, 3 March 1989 (1989-03-03), pages 1178 - 1185, XP002149098, ISSN: 0022-3263 * |
RUEGER H ET AL: "A convergent synthesis approach towards CGP60536B, a non-peptide orally potent renin inhibitor, via an enantiomerically pure ketolactone intermediate", TETRAHEDRON LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 41, no. 51, 16 December 2000 (2000-12-16), pages 10085 - 10089, XP004225222, ISSN: 0040-4039 * |
SANDHAM D A ET AL: "A convergent synthesis of the renin inhibitor CGP60536B", TETRAHEDRON LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 41, no. 51, 16 December 2000 (2000-12-16), pages 10091 - 10094, XP004225223, ISSN: 0040-4039 * |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003103653A1 (en) * | 2002-06-11 | 2003-12-18 | Elan Pharmaceuticals, Inc. | Methods of treating alzheimer's disease using aryl alkanoic acid amides |
WO2007006532A1 (en) | 2005-07-11 | 2007-01-18 | Novartis Ag | New pyrocatechin derivatives |
RU2470018C2 (en) * | 2005-07-11 | 2012-12-20 | Новартис Аг | New pyrocatechol derivatives |
GB2431649A (en) * | 2005-10-25 | 2007-05-02 | Novartis Ag | Alternative synthesis of aryl-octanoyl amide compounds |
GB2431645A (en) * | 2005-10-25 | 2007-05-02 | Novartis Ag | Alternative synthesis of aryl-octanoyl amide compounds |
US8450519B2 (en) | 2005-10-28 | 2013-05-28 | Reuter Chemischer Apparatebau Kg | Process for preparing octenoic acid derivatives |
US8445708B2 (en) | 2005-10-28 | 2013-05-21 | Reuter Chemischer Apparatebau Kg | Process for preparing chiral octenoic acid derivatives |
US7872153B2 (en) | 2006-03-21 | 2011-01-18 | Novartis Ag | Salt of aliskiren with sulfuric acid |
WO2008061622A1 (en) * | 2006-11-07 | 2008-05-29 | Novartis Ag | Crystalline forms of aliskiren hemifumarate |
US8119841B2 (en) | 2006-11-07 | 2012-02-21 | Novartis Ag | Crystalline forms of aliskiren hemifumarate |
AU2007323465B2 (en) * | 2006-11-07 | 2011-08-04 | Novartis Ag | Crystalline forms of aliskiren hemifumarate |
EP1958666A1 (en) | 2007-02-13 | 2008-08-20 | Speedel Experimenta AG | Heterocyclic-substituted alkanamides as therapeutic compounds |
DE102007049039A1 (en) | 2007-10-11 | 2009-04-16 | Reuter Chemischer Apparatebau Kg | Process for the preparation of 8-hydrazino-8-aryl-octanoyl derivatives and their use |
WO2009064479A1 (en) * | 2007-11-13 | 2009-05-22 | Teva Pharmaceutical Industries Ltd. | Polymorphic forms of aliskiren hemifumarate and process for preparation thereof |
EP2062874A1 (en) | 2007-11-20 | 2009-05-27 | KRKA, tovarna zdravil, d.d., Novo mesto | Process and intermediates for the preparation of aliskiren |
EP2189442A1 (en) | 2008-11-20 | 2010-05-26 | Krka Tovarna Zdravil, D.D., Novo Mesto | Process and intermediates for the preparation of aliskiren |
WO2010089105A2 (en) | 2009-02-05 | 2010-08-12 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Moisture-activated granulation process |
US8203005B2 (en) | 2009-10-29 | 2012-06-19 | Carbo Design Llc | Manufacturing process for enantiomerically pure 8-aryloctanoic acids as Aliskiren |
EP2551260A1 (en) | 2011-07-28 | 2013-01-30 | Chemo Ibérica, S.A. | Chemical process for opening ring compounds |
WO2013014191A1 (en) | 2011-07-28 | 2013-01-31 | Chemo Iberica, S. A. | Chemical process for opening ring compounds |
US8703976B2 (en) | 2011-10-02 | 2014-04-22 | Milan Soukup | Manufacturing process for 8-aryloctanoic acids such as Aliskiren |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6730798B2 (en) | Process for the preparation of substituted octanoyl amides | |
AU2001273763A1 (en) | Process for the preparation of substituted octanoyl amides | |
US6800769B2 (en) | Process for the preparation of substituted octanoyl amides | |
US7132569B2 (en) | Preparation of N-substituted 2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoyl amides | |
US6670507B2 (en) | Process for the preparation of aryloctanoyl amides | |
EP2189442B1 (en) | Process and intermediates for the preparation of aliskiren | |
JP2003506425A (en) | Method for producing nitroxyalkyl ester of naproxen | |
WO2008090046A1 (en) | Alternate process for preparing 3,5-di-omicron-acyl-2-fluoro-2-c-methyl-d-ribono-gamma-lactone | |
JP2003335731A (en) | New carboxylic acid anhydride and method for synthesizing ester and lactone using the same | |
JP3046401B2 (en) | 6- [1- (N-Alkoxyimino) ethyl] salicylic acid derivative and method for producing the same | |
ZA200300018B (en) | Process for the preparation of substituted octanoyl amides. | |
KR940009527B1 (en) | Process for preparing 2-£2'-aminothiazole-4'-yl|-2-(alkoxyimino) acetate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 523088 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: IN/PCT/2002/01778/MU Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020027017207 Country of ref document: KR Ref document number: 2001273763 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2002/012628 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001940047 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 153717 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2414847 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003/00018 Country of ref document: ZA Ref document number: 200300018 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10312987 Country of ref document: US Ref document number: 018122817 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 1020027017207 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2001940047 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWP | Wipo information: published in national office |
Ref document number: 523088 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 523088 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 187795 Country of ref document: IL Ref document number: 187796 Country of ref document: IL |